Risk of Venous Thromboembolism Events in Postmenopausal Women Using Oral Versus Non-oral Hormone Therapy: A Systematic Review and Meta-Analysis

2018 ◽  
Vol 6 (6) ◽  
pp. 803
Author(s):  
D. Rovinski ◽  
R.B. Ramos ◽  
T.M. Fighera ◽  
G.K. Casanova ◽  
P.M. Spritzer
Keyword(s):  
Systematic Review ◽  
Venous Thromboembolism ◽  
Hormone Therapy ◽  
Postmenopausal Women ◽  
Meta Analysis ◽  
Thromboembolism Events

scholarly journals Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis

BMJ ◽  
2008 ◽  
Vol 336 (7655) ◽  
pp. 1227-1231 ◽  
Author(s):  
Marianne Canonico ◽  
Geneviève Plu-Bureau ◽  
Gordon D O Lowe ◽  
Pierre-Yves Scarabin
Keyword(s):  
Systematic Review ◽  
Hormone Replacement Therapy ◽  
Venous Thromboembolism ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Meta Analysis ◽  
Hormone Replacement

scholarly journals Venous thromboembolism in COVID-19: A systematic review and meta-analysis

2021 ◽  
pp. 1358863X2199556
Author(s):  
Anastasios Kollias ◽  
Konstantinos G Kyriakoulis ◽  
Styliani Lagou ◽  
Evangelos Kontopantelis ◽  
George S Stergiou ◽  
...  
Keyword(s):  
Systematic Review ◽  
Venous Thromboembolism ◽  
Meta Analysis ◽  
Vein Thrombosis ◽  
Increased Risk ◽  
Study Population ◽  
Meta Regression Analysis ◽  
Thromboembolism Events ◽  
Prophylactic Anticoagulation ◽  
Deep Vein

Severe coronavirus disease 2019 (COVID-19) is associated with increased risk of venous thromboembolism events (VTE). This study performed a systematic review in PubMed/EMBASE of studies reporting the prevalence of VTE in patients with COVID-19 who were totally screened/assessed for deep vein thrombosis (DVT) and/or for pulmonary embolism (PE). Among 47 candidate studies ( n = 6459; 33 in Europe), 17 studies ( n = 3973; weighted age 63.0 years, males 60%, intensive care unit (ICU) 16%) reported the prevalence of PE with a pooled estimate of 32% (95% CI: 25, 40%), and 32 studies ( n = 2552; weighted age 62.6 years, males 57%, ICU 49%) reported the prevalence of DVT with a pooled estimate of 27% (95% CI: 21, 34%). A total of 36 studies reported the use of at least prophylactic antithrombotic treatment in the majority of their patients. Meta-regression analysis showed that the prevalence of VTE was higher across studies with a higher percentage of ICU patients and higher study population mean D-dimer values, and lower in studies with mixed dosing of anticoagulation in ⩾ 50% of the population compared to studies with standard prophylactic dosing of anticoagulation in < 50% of the population. The pooled odds ratio for death in patients with COVID-19 and VTE versus those without VTE (17 studies, n = 2882) was 2.1 (95% CI: 1.2, 3.6). Hospitalized patients with severe COVID-19 are at high VTE risk despite prophylactic anticoagulation. Further research should investigate the individualized VTE risk of patients with COVID-19 and the optimal preventive antithrombotic therapy. PROSPERO Registration No.: CRD42020185543.

Sign in / Sign up

Export Citation Format

Share Document